Introduction Agents that cause damage to DNA (DNA damageinducing (DDI) agents) arrest cell cycle progression in all eukaryotes from yeast to humans at positions in late GI and G2 that have become known as "checkpoints" (Hartwell and Weinert, 1989; Murray, 1992;  Sheldrick and Carr, 1993;  Weinert and Lydall, 1993) , presumably to allow time for DNA repair. Otherwise the DNA damage would become irreversibly fixed as a consequence of DNA replication in S phase, or through cell division at mitosis (M phase).
characterized (O'Connor and Kohn, 1992) , but the key observation that tumor cells with mutant p53 were unable to arrest in G1 (Kastan et al., 1991) quickly led to an outline of the mammalian The mammalian G2 checkpoint mechanism is not yet well G1 checkpoint mechanism (Hunter, 1993;  Appella et al., this volume) . The p53 tumor suppressor gene is a transcription factor that normally is relatively inactive because it is rapidly degraded (Levine, 1993) . However, in response to exposure to ultraviolet light, ionizing radiation, and other DDI agents, the p53 protein is transiently stabilized, accumulates in the cell nucleus, and induces the expression of several genes including WAFl and GADD45 (El-Deiry et al., 1993;  El- Deiry et al., 1994) . The 21 kDa product of WAFl is a potent inhibitor of the cyclin-dependent protein kinases that are needed for the transition from G1 to S phase and for continued DNA replication in S (DuliC et al., 1994; Harper et al., 1993) .
Although the G1 checkpoint mechanism probably is much more complex, the induction of WAFl provides a simple explanation of how cell cycle progression can be arrested.
about 50 other genes are known to be induced in mammalian cells
In addition to WAF1,
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after exposure to DDI agents (Fornace, 1992;  Herrlich and Rahmsdorf, 1994) . Recent studies indicate that some genes are induced as a consequence of the effects of DDI agents on other cellular molecules and not necessarily as a consequence of damage to DNA (Anderson, 1994; Herrlich, and Rahmsdorf, 1994; Sachsenmaier et al., 1994) . Such exposures activate cytoplasmic signaling mechanisms that operate through protein kinase cascades initiated at or near the plasma membrane; in turn, these kinase cascades activate several transcription factors including AP1 and
Nevertheless, there is strong evidence that the p53-dependent induction of WAF1 is a direct consequence of the production of DNA strand breaks (Nelson and Kastan, 1994) and that DNA strand breaks are the signals f o r activation of the GI checkpoint(s) in yeast .
Although much has been learned about the structure and function of p53 and the probable sequence of subsequents events that lead to cell cycle arrest, little is known about how DNA damage is detected and the nature of the signal that is generated by DNA damage. Circumstantial evidence suggests that protein kinases may be involved. Indeed, several yeast kinase genes were identified by screening for mutants defective in their ability to
arrest cell cycle progression after exposure to DDI agents (Walworth et al., 1993; Weinert et al., 1994; Allen et al., 1994; Anderson, 1994) . In mammalian cells, the situation is less clear; however, in hamster cells, 2-aminopurine overrides the G1, S, and G2 checkpoints, and 2-aminopurine and H7, another protein kinase inhibitor, block DDI-agent induction of the GADD45 gene (Andreassen and Margolis, 1992; Luethy and Holbrook, 1994 Gottlieb and Jackson, 1993; Anderson, 1993) . The large DNA-PK, polypeptide and DNA-activated kinase activity co-purify (LeesMiller et al., 1990; Carter et al., 1990 analogues fluorosulfonylbenzoyladenosine (FSBA) and azido-ATP;
FSBA inhibits DNA-PK kinase activity .
A monoclonal antibody specific for the DNA-PK, polypeptide depleted DNA-dependent kinase activity from HeLa extracts (Carter et al., 1990 Ku was first recognized as a heterodimeric ( p 7 0 / p 8 0 ) , nuclear, phosphoprotein that reacted with sera from patients suffering from the autoimmune diseases lupus erythematosus and scleroderma polymyositis (Mimori et al., 1981; Reeves, 1992) .
HeLa cells contain -400,000 molecules of Ku per cell (Mimori et al., 1986) , but Ku also appears to be less abundant in nonprimate cells and was not detected in mouse L-929 cells using mouse-specific monoclonal antibodies (Wang et al., 1993) . In vitro Ku binds initially to the ends of linear DNA fragments but then can translate along the DNA in an ATP-independent manner (de Vries et al., 1989) . Ku also recognizes DNAs with nicks and gaps, as well as DNAs with single-to double-strand transitions (Blier et al., 1993; Falzon et al., 1993) , and these structures activate DNA-PK (Morozov et al., 1994) . cDNAs for the two Ku polypeptides have been cloned and sequenced from both human and mouse cells (Chan et al., 1988; Reeves and Sthoeger, 1989; Yaneva et al., 1989; Mimori et al., 1990; Griffith et al., 1992; Porges et al., 1990; Falzon and Kuff, 1992) , and the human genes recently were mapped to chromosomes 2 (p80) and 22 (p70) (Cai et al., 1994) . The location of the p80 Ku subunit gene corresponds to the location of the human gene (XRCC5) that complements ionizing-radiation sensitivity in group 5 hamster cells.
Transfection of the cDNA for the human Ku p80 subunit into group 5 hamster cells that are defective in repairing double strand breaks restored their X-ray sensitivity to normal levels and corrected the defect in site-specific recombination (Rathmell and Chu, 1994a,b; Getts and Stamato, 1994; Taccioli et al., 1994) .
Thus, Ku is likely to play a role in these processes. It may protect DNA ends from exonucleolytic degradation; however, by activating DNA-PK, it also might have other signaling functions.
Recently, Ku was shown to have DNA helicase activity and to be identical to a previously described activity, human DNA helicase I1 (Tuteja et al., 1994) ; thus, Ku probably also performs functions that are independent of DNA-PK,. Anderson, 1993; Jackson et al., 1993) . However, for most of these proteins, the sites that are phosphorylated by DNA-PK are not known.
To determine if the sites that were phosphorylated -in vitro also were phosphorylated in vivo and if DNA-PK recognized a preferred protein sequence, we identified the sites phosphorylated by DNA-PK in several substrates by direct protein sequence analysis. phosphorylation sites.
is followed immediately by glutamine in the polypeptide chain; at no other positions are the amino acid residues obviously (Chen et al., 1991) . Isolation of the phosphopeptides containing these residues was accomplished using iron-affinity chromatography in conjunction with conventional reverse phase HPLC. The phosphorylated serines then were identified by direct sequence analysis after converting the phosphoserine to Sethylcysteine. Each phosphorylated TAg serine is followed .
immediately by glutamine ( TAg, or the human serum response factor (SRF). Two serines followed by glutamine in a peptide derived from the carboxyterminal transactivation domain of SRF are phosphorylated by DNA-PK, and they also appear to be phosphorylated in serum-stimulated cells (Liu et al., 1993) .
To examine further the role of glutamine in site recognition, we examined the ability of DNA-PK to phosphorylate synthetic peptides corresponding to segments of the human p53 protein sequence.
phosphorylation sites in human p53, including serines 9, 15, 33, 315, and 392, and all -SQ-or -QS-sites (i.e. S15, -LSQE-; S37,
-PSQA-, S99, -PSQK-, S166, QSQH, and S376, GQSTS) (Lees-Miller et a l . , 1992).
motifs were phosphorylated by DNA-PK; one of these, serine 15, is in a highly conserved region and is phosphorylated in vivo (Ullrich et al., 1993) . The sequence requirements for phosphorylation at this site were examined in more detail using a series of synthetic peptides ( Figure 1 ).
A second substrate determinant for recognition by DNA-PK is the ability to bind DNA. Jackson et al. first observed that quantitative phosphorylation of Spl required a DNA template with a GC-box DNA binding element (Jackson et al., 1990) .
Anderson et al., Methods Protein Structure Analysis 11/5/94
Subsequently it was found that efficient phosphorylation required that both DNA-PK and Spl be bound to the same DNA molecule (Figure 2 ). The POU domain has two sites that resemble other identified DNA-PK phosphorylated sites, a TQ at residues 44/45 and an SQ at residues 61/62. Phosphoamino acid analysis revealed only phosphoserine (data not shown); thus, the TQ sequence is not a DNA-PK phosphorylation site. After digestion with trypsin and CNBr, none of the phosphopeptides were retained on a C18 reverse phase column, but after digestion with trypsin alone, a major, modestly hydrophobic phosphopeptide was retained by the reverse phase column (Figure 3 ) . Amino-terminal sequence analysis showed that this peptide was derived from the amino terminus of the expressed protein and that the serine at position 3 was partially phosphorylated. These findings are consistent with the HPLC data shown in Figure 3 ; after digestion with CNBr and trypsin, serine 3 would be in the tripeptide AlaSer-Met* (Met* = homoserine). We cannot formally exclude serine 22 as a possible second site of phosphorylation; after digestion with both CNBr and trypsin, it would be present in the tetrapeptide Ser-Gly-Gly-Met* .
derivative containing serine 22 but lacking the serine 3 site was not phosphorylated by DNA-PK. Serine 3 lies outside the POU domain and is not followed by a glutamine, but, in this case, the However, another Oct-1/POU .
non-specific DNA binding ability of the POU domain may be sufficient to drive phosphorylation of this non-physiological, vector-encoded site. Distinguishing between physiological and non-physiological substrates and sites may well be even more difficult for DNA-PK than for other protein kinases.
Our results with the POU domain protein raise the issue of whether in vivo DNA-PK also phosphorylates serines or threonines and several putative CTD kinases have been described (Dhamus and Dynan, 1992; O'Brien et al., 1994) .
A CTD peptide consisting of four heptad repeats, (YSPTSPS)4RRR, is phosphorylated by purified human DNA-PK, although the Km for this peptide substrate is above 1 mM. The CTD peptide was phosphorylated exclusively on serine (data not shown), and sequence analysis (Figure 4 ) revealed that the major site of phosphorylation was the serine at position 7, or the equivalent serine in the second (and probably at the third and fourth) repeat. These serines are followed in the repeat by tyrosine; however, tyrosine did not efficiently substitute for glutamine in the p53-derived sequence ( Table 2 ). The GAL4-CTD protein was reported to be phosphorylated at both serine and threonine (Dvir et al., 1993) ; thus, the number of repeats, the DNA template, or other factors may influence the recognition of sites by DNA-PK.
Another consideration with regard to substrate recognition is that some sites phosphorylated in vivo may not be phosphorylated in vitro. We alluded to a possible case in SV40
TAg. Serine 639 is phosphorylated in vivo and resembles other DNA-PK sites, but no kinase has been identified that phosphorylates this site in vitro (Chen et al., 1991) .
vivo TAg assembles into a dodecameric structure at the SV40 origin of replication, whereas, in our in vitro experiments, calf thymus DNA was used as the DNA-PK activator, and TAg most likely binds . In vitro assays indicated that total cellular DNA-PK activity changes only slightly with stage of the cell cycle, and no significant increase in activity was observed after HeLa cells were treated with DNA damage-inducing agents.
These observations suggest that DNA-PK normally may be inactive and that synthesis and degradation are not important mechanisms of regulating its activity.
occurs as a consequence of changes to chromatin that create entry sites f o r the Ku DNA-binding, regulatory subunit. Such changes may be caused by normal cellular activities including transcription, replication or recombination, or they may be a consequence of damage to DNA that is caused by endogenous or
We presume that DNA-PK activation exogenous agents.
autophosphorylation , other posttranslational events, or through the synthesis or activation of inhibitors . Because the methods used to disrupt cells in preparing extracts inevitably fragments chromatin, it has not been possible to determine the state of activation of DNA-PK with existing in vitro assays. 
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